Catalyst Pharmaceuticals Stock Today
| CPRX Stock | USD 15.13 0.21 1.37% |
Performance1 of 100
| Odds Of DistressLess than 2
|
Catalyst Pharmaceuticals is trading at 15.13 as of the 19th of April 2024; that is -1.37 percent decrease since the beginning of the trading day. The stock's open price was 15.34. Catalyst Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Catalyst Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of January 2024 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of November 2006 | Category Healthcare | Classification Health Care |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. Catalyst Pharmaceuticals, Inc. The company has 118.01 M outstanding shares of which 6.05 M shares are currently shorted by private and institutional investors with about 3.91 trading days to cover. More on Catalyst Pharmaceuticals
Moving against Catalyst Stock
| 0.69 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Catalyst Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Catalyst Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Catalyst Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Richard MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Catalyst Pharmaceuticals report their recommendations after researching Catalyst Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Catalyst Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Catalyst Pharmaceuticals. The Catalyst consensus assessment is calculated by taking the average forecast from all of the analysts covering Catalyst Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Catalyst Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Catalyst Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in May. Financial strength of Catalyst Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalyst Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Catalyst Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Catalyst Pharmaceuticals' financial leverage. It provides some insight into what part of Catalyst Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Catalyst Pharmaceuticals (CPRX) is traded on NASDAQ Exchange in USA. It is located in 355 Alhambra Circle, Coral Gables, FL, United States, 33134 and employs 167 people. Catalyst Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.81 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Catalyst Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Catalyst Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Catalyst Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 118.01 M outstanding shares of which 6.05 M shares are currently shorted by private and institutional investors with about 3.91 trading days to cover.
Catalyst Pharmaceuticals currently holds about 220.79 M in cash with 143.6 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.15.
Check Catalyst Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationCatalyst Pharmaceuticals retains a total of 118.01 Million outstanding shares. The majority of Catalyst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Catalyst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Catalyst Pharmaceuticals. Please pay attention to any change in the institutional holdings of Catalyst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Catalyst Ownership Details
Catalyst Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Catalyst Pharmaceuticals jumping above the current price in 90 days from now is about 48.87%. The Catalyst Pharmaceuticals probability density function shows the probability of Catalyst Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9669 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Catalyst Pharmaceuticals will likely underperform. Additionally, catalyst Pharmaceuticals has an alpha of 0.0096, implying that it can generate a 0.009574 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Catalyst Pharmaceuticals to move above the current price in 90 days from now is about 48.87 (This Catalyst Pharmaceuticals probability density function shows the probability of Catalyst Stock to fall within a particular range of prices over 90 days) .
Catalyst Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Catalyst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Catalyst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Catalyst Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2023-12-31 | 1.4 M | |
| Jacobs Levy Equity Management, Inc. | 2023-09-30 | 1.3 M | |
| Opaleye Management Inc | 2023-12-31 | 1.3 M | |
| Lsv Asset Management | 2023-12-31 | 1.2 M | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 1.2 M | |
| Hhg Plc | 2023-12-31 | 1.1 M | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 956.3 K | |
| Amvescap Plc. | 2023-12-31 | 919.6 K | |
| American Century Companies Inc | 2023-12-31 | 917.6 K | |
| Blackrock Inc | 2023-12-31 | 15.8 M | |
| Deerfield Management Co | 2023-09-30 | 8.2 M |
Catalyst Pharmaceuticals Historical Income Statement
Catalyst Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Catalyst's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Catalyst Pharmaceuticals revenue and expense. Catalyst Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Catalyst Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 49.4 M in 2024, whereas Net Interest Income is likely to drop slightly above 1 M in 2024. View More FundamentalsCatalyst Stock Against Markets
Picking the right benchmark for Catalyst Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Catalyst Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Catalyst Pharmaceuticals is critical whether you are bullish or bearish towards Catalyst Pharmaceuticals at a given time. Please also check how Catalyst Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Catalyst Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Catalyst Pharmaceuticals Corporate Directors
Catalyst Pharmaceuticals corporate directors refer to members of a Catalyst Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Catalyst Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Catalyst Pharmaceuticals' board members must vote for the resolution. The Catalyst Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Donald Denkhaus | Director | Profile | |
| Charles OKeeffe | Lead Independent Director | Profile | |
| David Tierney | Independent Director | Profile | |
| Philip Coelho | Independent Director | Profile |
How to buy Catalyst Stock?
Before investing in Catalyst Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Catalyst Pharmaceuticals. To buy Catalyst Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Catalyst Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Catalyst Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Catalyst Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Catalyst Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Catalyst Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Already Invested in Catalyst Pharmaceuticals?
The danger of trading Catalyst Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Catalyst Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Catalyst Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Catalyst Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.